Skip to main content

Table 4 Summary results for efficacy variables

From: Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma

   Before PAa After PA Overall
EFS b     
  Median 6.3 (3.3-10.5) 8.1 (4.1 - 19.7) 6.9 (5.0-10.5)
  1-year Rate 23.8 (8.2-47.2) 39.4 (22.9-57.9) 33.3 (21.1-47.5)
  2-year Rate 14.3 (3.6-32.1) 30.3 (15.9-46.1) 24.1 (13.7-36.0)
PFS c     
  Median 6.6 (5.0-11.0) 11.9 (6.9-26.9) 8.6 (6.3-14.4)
  1-year Rate 28.6 (11.7-48.2) 48.5 (30.8-64.1) 40.7 (27.7-53.4)
  2-year Rate 19.1 (5.9-37.7) 39.4 (23.1-55.4) 31.5 (19.7-43.9)
OS d     
  Median 12.6 (6.9-21.1) NA 15.5 (11.0-NA)
TTR e     
  Median 2.8 (1.4-5.1) 7.6 (4.1-8.9) 4.8 (2.5-8.0)
  1. a Protocol Amendment; b Event-free Survival; c Progression-free Survival; d Overall Survival; e Time to Tumor Response.
  2. Overall results are presented as well as results stratified by time of enrollment in the study with respect to the protocol amendment. Results are expressed in months (95% CI) for median variables and as percentage (95% CI) for 1- and 2-year rates.